Sirtuin-1 targeting promotes Foxp3+ T-regulatory cell function and prolongs allograft survival

Molecular and Cellular Biology

Volumn 31, Issue 5, 2011, Pages 1022-1029

  Beier, Ulf H ^a   Wang, Liqing ^a   Bhatti, Tricia R ^a   Liu, Yujie ^a   Han, Rongxiang ^a   Ge, Guanghui ^a   Hancock, Wayne W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYTOKINE; SIRTUIN 1; TRANSCRIPTION FACTOR FOXP3;

ALLOGRAFT; ANIMAL CELL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; GENE DELETION; GRAFT SURVIVAL; HISTOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; WILD TYPE;

ANIMALS; CARBAZOLES; FORKHEAD TRANSCRIPTION FACTORS; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; INTEGRASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION; NAPHTHALENES; PYRONES; SIRTUIN 1; T-LYMPHOCYTES, REGULATORY;

MUS;

EID: 79952274915     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.01206-10     Document Type: Article

References (36)

1. Battke, F., S. Symons, and K. Nieselt. 2010. Mayday-integrative analytics for expression data. BMC Bioinformatics 11:121.
2. Bettelli, E., et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235-238.
3. Cheng, H. L., et al. 2003. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100:10794-10799.
4. Dardalhon, V., et al. 2008. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat. Immunol. 9:1347-1355.
5. de Zoeten, E. F., L. Wang, H. Sai, W. H. Dillmann, and W. W. Hancock. 2010. Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138:583-594.
6. Donmez, G., and L. Guarente. 2010. Aging and disease: connections to sirtuins. Aging Cell 9:285-290.
7. Frye, R. A. 1999. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem. Biophys. Res. Commun. 260:273-279.
8. Haigis, M. C., and D. A. Sinclair. 2010. Mammalian sirtuins: biological insights and disease relevance. Annu. Rev. Pathol. 5:253-295.
9. Jung, K. J., et al. 2009. Effect of short term calorie restriction on proinflammatory NF-kB and AP-1 in aged rat kidney. Inflamm. Res. 58:143-150.
10. Lara, E., et al. 2009. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 28:781-791.
11. Lee, P. P., et al. 2001. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15:763-774. (Pubitemid 34008504)
12. Libermann, T. A., and D. Baltimore. 1990. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol. Cell. Biol. 10:2327-2334.
13. Liu, T., P. Y. Liu, and G. M. Marshall. 2009. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702-1705.
14. Milne, J. C., et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716. (Pubitemid 350207685)
15. Nadig, S. N., et al. 2010. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat. Med. 16:809-813.
16. Neugebauer, R. C., et al. 2008. Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J. Med. Chem. 51:1203-1213.
17. Purushotham, A., et al. 2009. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:327-338.
18. Reardon, C., A. Wang, and D. M. McKay. 2008. Transient local depletion of Foxp3+ regulatory T cells during recovery from colitis via Fas/Fas ligand-induced death. J. Immunol. 180:8316-8326.
19. Ruan, Q., et al. 2009. Development of Foxp3(+) regulatory T cells is driven by the c-Rel enhanceosome. Immunity 31:932-940.
20. Rubtsov, Y. P., et al. 2008. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity 28:546-558.
21. Sadlon, T. J., et al. 2010. Genome-wide identification of human FOXP3 target genes in natural regulatory T cells. J. Immunol. 185:1071-1081.
22. Sakaguchi, S., K. Wing, and T. Yamaguchi. 2009. Dynamics of peripheral tolerance and immune regulation mediated by Treg. Eur. J. Immunol. 39:2331-2336.
23. Schug, T. T., et al. 2010. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell. Biol. 30:4712-4721.
24. Sequeira, J., et al. 2008. Sirt1-null mice develop an autoimmune-like condition. Exp. Cell Res. 314:3069-3074.
25. Solomon, J. M., et al. 2006. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol. Cell. Biol. 26:28-38.
26. Tao, R., et al. 2007. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med. 13:1299-1307.
27. Tao, R., et al. 2005. Differential effects of B and T lymphocyte attenuator and programmed death-1 on acceptance of partially versus fully MHC-mismatched cardiac allografts. J. Immunol. 175:5774-5782. (Pubitemid 41508061)
28. van Loosdregt, J., et al. 2010. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood 115:965-974.
29. Vaquero, A., and D. Reinberg. 2009. Calorie restriction and the exercise of chromatin. Genes Dev. 23:1849-1869.
30. Wang, L., E. F. de Zoeten, M. I. Greene, and W. W. Hancock. 2009. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat. Rev. Drug Discov. 8:969-981.
31. Westerheide, S. D., J. Anckar, S. M. Stevens, Jr., L. Sistonen, and R. I. Morimoto. 2009. Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323:1063-1066.
32. Williams, J. A., et al. 2005. Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint. J. Immunol. 175:4199-4207. (Pubitemid 41361953)
33. Yoshizaki, T., et al. 2010. SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. Am. J. Physiol. Endocrinol. Metab. 298:E419-E428.
34. Zhang, J., et al. 2009. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest. 119:3048-3058.
35. Zhang, R., et al. 2010. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem. 285:7097-7110.
36. Zhou, L., et al. 2007. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967-974.